Biomarkers for Risk Stratification in Lung Cancer

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 590 → 1440 participants
    • Eligibility criteria expanded, about 11 words
    • Study description expanded, about 9 words
  2. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2030v7
  3. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v6
  4. Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v5
  5. Re-verified, no change to tracked fieldsv4
Show 2 earlier versionsHide 2 earlier versions
  1. Eligibility criteria expanded, about 4 words
    • Study description expanded, about 5 words
    v3
  2. Site contacts updated at 3 of 3 sitesv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.
Trial Details
NCT Number NCT03774758
Lead Sponsor University of California, San Francisco
Collaborators: Northern California Institute of Research and Education, Guardant Health, Inc.
Conditions
(from sponsor)		 Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung, Solitary Pulmonary Nodule
Enrollment 1,440 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov